Exkivity
Takeda writes off $770M after failures of Alofisel and Exkivity
Anika Sharma
Takeda, the Japanese pharmaceutical company, is grappling with significant impairment charges totaling 115.8 billion Japanese yen ($770 million) in its ...
Takeda withdraw Global Lung Cancer Medication, Exkivity, Following Confirmatory Trial Failure
Anika Sharma
Following a disappointing outcome in a confirmatory trial earlier this year, Takeda has decided to discontinue its targeted non-small cell ...
